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hen Can
oninferior Be Superior?
he Multidimensional Nature of
linical Decision-Making Calls for
nnovative Approaches to Clinical Trials*
. Magnus Ohman, MD, Robert M. Califf, MD
urham, North Carolina
he use of drug-eluting stents (DES) has dramatically
hanged the face of interventional cardiology with a sub-
tantial reduction in repeat revascularization procedures.
owever, there has not been a reduction in the major
ardiovascular events such as death and myocardial infarc-
ion (MI) with the first-generation drug-eluting stents
sirolimus-eluting stent [SES] and paclitaxel-eluting stent
PES]) up to 4 years after implantation (1). Also observed in
hese first waves of randomized trials was a low, but a
tatistically significant higher rate of late stent thrombosis
after 1 year when compared with bare-metal stents
BMS]), and this difference may be altered by continuous
xposure to aspirin and a P2Y12 inhibitor. There was a
onsiderable uptake of the first-generation DES based on
he larger effect on restenosis, but the rate of uptake was
lunted because of concerns about late stent thrombosis and
wareness of the absence of effect on death and MI. This
as followed by the second-generation of DES (everolimus-
luting stent [EES] and zotarolimus-eluting stent [ZES])
eing approved by the Food and Drug Administration in
008. Several third-generation DES are also now being
ested.
See page 543
We have now entered into a global discussion about
omparative effectiveness. The U.S. government currently
ses the following definition: “Comparative effectiveness
esearch is the conduct and synthesis of systematic research
omparing different interventions and strategies to prevent,
iagnose, treat and monitor health conditions. The purpose
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Duke University Medical Center, Duke University, Durham, Northf
arolina. For full disclosures for Drs. Ohman and Califf, please see www.dcri.
uke.edu/research/coi.jsp.f this research is to inform patients, providers, and
ecision-makers, responding to their expressed needs, about
hich interventions are most effective for which patients
nder specific circumstances. To provide this information,
omparative effectiveness research must assess a comprehen-
ive array of health-related outcomes for diverse patient
opulations (2).”
In this context, with regard to coronary stents, many
uestions exist: When should a stent be chosen in prefer-
nce to medical therapy or surgery? If one chooses a stent,
hich type is superior? Does the comparative balance of
enefit and risk vary as a function of patient or angiographic
haracteristics? Furthermore, the patient and his/her family,
he primary care and noninvasive physicians, and the hos-
ital and health system in addition to the interventional
ardiologists all have a stake in decision making.
Typically, the majority of interventional cardiologists pick
device based on personal experience with the device,
ombined with physical characteristics of the device in terms
f delivery to more complex lesions, findings from prospec-
ive comparative randomized clinical trials, and perceived
ffects in patients with particular characteristics from either
ubstudies or individual studies. Much of the literature has
ocused on diabetes and complex lesion morphology as key
ifferentiating factors. In the U.S., very few interventional
ardiologists use price point for decisions on selection for
ndividual patients, whereas health care systems often pref-
rentially stock devices that are at more favorable pricing as
ong as the DES selected are felt to be similar to the
redicated devices (first-generation stents).
Given the rapid shift of American cardiology practices to
n employee status within health systems, and the domi-
ance of this model in other parts of the world, the
hallenge of deciding when a device is “similar” is quite
aunting and critical to the health of our patients. Although
he word “similar” has no statistical meaning, statistical
esting for “similar outcomes” involves a methodology that
as been called noninferiority or equivalence testing. In the
ormer, the hypothesis is that the new stent should not
erform worse than pre-set criteria; therefore, the implicit
ypothesis is that the device is not worse than the standard
evice. The term “equivalence” is usually considered in a
-sided analysis (as opposed to noninferiority that only uses
-sided testing). Thus, a stent can be found to be non-
quivalent because it is either worse or better.
As the hurdle for noninferiority testing is strict and
equires prior determination of boundaries of acceptable
ifference between devices, it typically requires a larger
umber of patients to be randomized. Importantly, with
oth equivalence and noninferiority hypothesis testing, one
ould pre-specify that one would test for superiority if the
rial met the noninferiority criteria. In this sequential testing
pproach, one can initially test for noninferiority, and if this
urdle is met, without loss of statistical power (alpha), a
ormal test for superiority can be done. Implicit in the
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When Can Noninferior Be Superior? February 9, 2010:555–7ypothesis testing using a 1-sided noninferiority testing
trategy is that one does not hypothesize that the stent is
etter unless one pre-specifies this as an analysis.
The issue becomes even more complex when one consid-
rs that it is not only possible, but likely that different
omponents of a classic cardiovascular composite end point
re influenced differently by 1 stent compared with another.
he testing of a composite for noninferiority leaves little
oom to further examine differences in specific components,
lthough this could be theoretically possible.
There is substantial knowledge of the performance of the
ajority of currently available DES from numerous angio-
raphic studies. An interesting picture has emerged with a
elative order of in-stent late loss. This is an important
arameter that is directly associated with subsequent rates of
arget vessel revascularization (TVR). Pocock et al. (3)
erformed an analysis from 11 multicenter randomized
tent trials comparing DES with BMS from 5,381 patients.
hey found that in-stent late loss (ILL) was highly predic-
ive of the subsequent need for target lesion revasculariza-
ion during follow-up and suggested that ILL could be
eliably used as a surrogate end point for target lesion
evascularization. As already discussed, however, this ap-
roach is insufficient to inform decision making because it
oes not address the risk of death and MI that weigh more
eavily than the risk of restenosis.
Moreno et al. (4) have identified that the SES appears to
ave the lowest ILL (in millimeters) with a range of
pproximately 0.10 to 0.20 mm on follow-up angiographic
nalysis. Similarly, EES has values of 0.10 to 0.16 mm (5,6).
ES have had an ILL ranging from 0.30 to 0.40 mm in the
arly trials (4). Finally, ZES has had late loss of 0.34 to 0.62
7,8). Thus, of the first-generation DES, PES has had the
ighest ILL, whereas ZES has had the highest ILL loss
mong the second-generation stents. For comparison, the
LL among BMS in the early comparative trials has ranged
rom 0.63 to 1.05 mm, suggesting that the ILL of ZES is
loser to some BMS in overall comparison. Importantly, in
he prospective randomized trial (ENDEAVOR II) (8), the
LL was 1.03 mm with BMS and 0.61 with ZES, which
as a statistically significant difference (p  0.001).
In this issue of the Journal, Leon et al. (9) publish the
esults of the ENDEAVOR IV (Randomized Comparison
f Zotarolimus-Eluting and Paclitaxel-Eluting Stents in
atients with Coronary Artery Disease) trial, which was a
rospective, randomized comparison of ZES versus PES for
ingle de novo coronary artery lesion. The primary hypoth-
sis was a noninferiority test with regard to 9-month target
essel failure, which was defined as cardiac death, MI, or
VR. The ZES was found to be noninferior with a target
essel failure rate of 6.6% for ZES versus 7.1% for PES
p  0.001). This conclusion of noninferiority with regard
o the composite end point was driven by the combination
f fewer periprocedural MIs with ZES (0.5% vs. 2.2%, p 
.007), but with a numerically higher rate of in-segment
estenosis with ZES 15.3% versus 10.4%, (p  0.24). Based Fn these findings, Leon et al. (9) conclude that ZES has
imilar clinical safety and efficacy as PES among single de
ovo coronary lesions.
From the decision maker’s perspective, this trial raises the
uestion of whether ZES and PES are really similar or
hether the significant reduction of periprocedural MIs,
hich is highly significant, should be considered a superior
ttribute of ZES? The study had not set up an a priori
ypothesis testing for superiority for any individual end
oints; thus, in statistical terms, the most prudent conclu-
ion is that ZES is indeed noninferior and that a reduction
n MI observed is of interest but can only be hypothesis-
enerating and should be tested in another trial. Tantalizing
n this regard is the fact that in the ENDEAVOR III
Randomized Comparison of the Endeavor ABT-578 Drug
luting Stent with Bare Metal Stent for Coronary Revas-
ularization) trial, MI was also significantly reduced (0.6%
s. 3.5% with ZES compared with SES, p  0.04) but this
as from a much smaller experience of only of 436 patients
7). In both the ENDEAVOR III and IV trials, the rate of
n-segment restenosis was numerically higher but statisti-
ally so only in the ENDEAVOR III trial. Thus, the
ombined trial experience to date suggests that ZES may
ndeed have a positive effect on periprocedural MI but an
ntoward effect on late segment loss and/or restenosis.
The EES is another second-generation stent that also has
een evaluated in large-scale clinical trials. Similarly, the
ivotal SPIRIT III (Clinical Evaluation of the Xience V
verolimus Eluting Coronary Stent System in the Treat-
ent of Patients with de novo Native Coronary Artery
esions) trial was also a 1-sided noninferiority study but
ith a pre-specified superiority testing if noninferiority was
et (5). The ILL was 0.16 mm for EES compared with
.30 mm for PES (p 0.002). The composite major cardiac
vents were reduced at 1 year (6.0% vs. 10.3%, p  0.02),
hich was confirmed at the 2-year follow-up (10) with a
ignificant 32% reduction in target vessel failure (10.7% vs.
5.4%, p  0.04), and a 45% reduction in major cardiovas-
ular events (cardiac death, MI, target lesion revasculariza-
ion, 7.3% vs. 12.8%, p  0.004). Thus, both the second-
eneration stents appear to have trend toward superiority for
he hard clinical end points but EES, when compared to
ES, appears to have a more favorable ILL.
How do the interventional cardiologist and the multiple
ther decision makers now choose a device for the individ-
al patient? Both stents are by statistical study design
oninferior, both for ILL as well as for target vessel failure,
efined as death, MI, and TVR. Both show tantalizing
enefits, such as reduction in MI, which incidentally was
ot shown in the BMS versus DES trials up to 4 years.
ome physicians will be swayed by the larger difference in
he composite benefit observed with EES, whereas others
ill be swayed by the reduction in MI by ZES, but none of
his is conclusive. Part of the issue at hand is the relatively
mall sample size of these second-generation stent trials.
urthermore, they both were designed as noninferiority
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February 9, 2010:555–7 When Can Noninferior Be Superior?rials and, in the case of the SPIRIT trials, with a pre-
pecified idea that possibly EES might be superior. No such
equential testing was part of the statistical approach for
ES.
Our belief is that the best approach to this conundrum is
o have more appropriately sized clinical end point-based
nvestigation to better capture the overall intent of compar-
tive research, namely improvement in significant clinical
nd points such as death, MI, and the need for subsequent
evascularization. Whereas these trials should be designed
o either capture superiority or true equivalence, the com-
lexity of the possible findings should not be dismissed
ecause rational and intelligent people often will value
ifferent parts of a composite end point in different ways.
or example, the significance of periprocedural MI in the
bsence of an obvious procedural complication continues to
e debated and some major debate continues about the
elative value of preventing a restenosis event precipitating
VR and an episode of stent thrombosis.
From the preceding discussion, it will also be apparent
hat there will be a strong interest to use ZES as the
omparator in future trials as it has the highest ILL of DES.
e would like to discourage manufacturers and researchers
rom this approach, but rather test it against the 2 devices
hat so far appear to have either the lowest late loss (SES) or
he stent with the better clinical outcomes (EES compared
ith the other first-generation stent, PES). Alternatively, a
ragmatic trial design would compare a new stent against
ny approved device, but the sample size with such a
eterogeneous control group would be substantially larger.
lthough this may be attractive from a clinical perspective,
t may not be either practical and/or easy to understand, as
hysicians will likely select certain lesion or patient charac-
eristics, for 1 of the control DES versus the other, making
ny comparison and subgroup analysis difficult to evaluate.
Our recommendation for any third- and fourth-
eneration DES is that the first hurdle should be that any
ew DES meets the stricter criteria of equivalence for ILL.
y defining equivalence, one will narrow the range to which
LL could be expected: for example, ILL of one-half of the
.54 mm, thus preserving at least 50% of the late loss when
ompared with BMS. Such a trial would be larger than a
oninferiority trial, but it would also possibly point toward
otential superiority. Once such a phase-2 program has
een defined, a larger phase-3 program driven purely by
linical end points and with superiority testing versus
K
zoninferiority followed by superiority testing for the third-
eneration DES might be considered. This stepwise ap-
roach would help guide the clinical trials’ methodology and
llow the most appropriate clinical trials to be used, which
ltimately will help physicians as DES technology matures.
ith increased certainty, our patients can also be more
ertain that they ultimately would get the best stent for their
linical condition and not have the difficult decision of
rading off a reduction in MI versus later restenosis.
eprint requests and correspondence: Dr. E. Magnus Ohman,
uke Heart Center, Duke University Medical Center, Cardiology,
oom 8676A HAFS Building, Duke Hospital Erwin Road, Box
126, Durham, North Carolina 27710. E-mail: ohman001@
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